0
No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > Protein > OX40 Ligand > OXL-H52Q8

Human OX40 Ligand / TNFSF4 Protein, His Tag, active trimer (MALS verified)

Order Now

  • Synonym
    OX40L,TNFSF4,CD252,Glycoprotein Gp34,TXGP1,CD134 ligand,CD134L
  • Source
    Human OX40 Ligand Protein, His Tag(OXL-H52Q8) is expressed from human 293 cells (HEK293). It contains AA Gln 51 - Leu 183 (Accession # NP_003317).
    Predicted N-terminus: His
  • Molecular Characterization
    OX40 Ligand Structure

    This protein carries a polyhistidine tag at the N-terminus.

    The protein has a calculated MW of 16.9 kDa. The protein migrates as 25-30 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
OX40 Ligand SDS-PAGE

Human OX40 Ligand Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS
OX40 Ligand MALS images

The purity of Human OX40 Ligand Protein, His Tag (Cat. No. OXL-H52Q8) is more than 95% and the molecular weight of this protein is around 60-80 kDa verified by SEC-MALS.

Bioactivity-ELISA
 OX40 Ligand ELISA

Immobilized Human OX40 Ligand Protein, His Tag (Cat. No. OXL-H52Q8) at 2 μg/mL (100 μL/well) can bind Human OX40, Fc Tag (Cat. No. OX0-H5255) with a linear range of 1-8 ng/mL (QC tested).

 OX40 Ligand ELISA

Immobilized Human OX40 Ligand Protein, His Tag (Cat. No. OXL-H52Q8) at 2 μg/mL (100 μL/well) can bind Biotinylated Human OX40, Fc,Avitag (Cat. No. OX0-H82F7) with a linear range of 10-78 ng/mL (Routinely tested).

Bioactivity-BLI
 OX40 Ligand BLI

Loaded Biotinylated Human OX40, Avitag,His Tag (Cat. No. TN4-H82E4) on SA Biosensor, can bind Human OX40 Ligand Protein, His Tag (Cat. No. OXL-H52Q8) with an affinity constant of 0.127 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

 OX40 Ligand BLI

Loaded Human OX40 Ligand Protein, His Tag (Cat. No. OXL-H52Q8) on AR2G Biosensor, can bind Human OX40, His Tag (Cat. No. OX0-H5224) with an affinity constant of 0.15 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

  • Background
    Tumor necrosis factor ligand superfamily member 4 (TNFSF4) is also known as glycoprotein Gp34, OX40 ligand (OX40L), TAX transcriptionally-activated glycoprotein 1 and CD252, which belongs to the tumor necrosis factor family. TNFSF4 is the ligand for CD134 and is expressed on such cells as DC2s (a subtype of dendritic cells) enabling amplification of Th2 cell differentiation. The interaction of TNFSF4-TNFSF4 is involved in the pathogenesis of multiple autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE), carotid artery disease and cancer. Furthermore, similar to other TNF superfamily members, membrane-bound OX40 Ligand (TNFSF4) exists as a homotrimer. Human TNFSF4 shares 46% amino acid sequence identity with its mouse counterpart.
  • Clinical and Translational Updates

Comments (0)


ETA de productos en stock: 2 días laborables

Price(EUR) : €380.00

Price(EUR) : €2890.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:7 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Email
Correo electrónico
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje